

CV Christophe CAUX

- Current position:
Team leader “Cancer Immune Surveillance and Therapeutic targeting”, Cancer Research Center of Lyon (CRCL) & LICL, “Laboratory of Immunotherapy of Cancer of Lyon”
- Identity and contact
Born: 23-01-1964 - Nationality: French
Contact : Centre Léon Bérard,
28 Rue Laennec - 69008 Lyon - FRANCE
Email ID: christophe.caux@Lyon.unicancer.fr

EDUCATION

- Baccalauréat (1982)
- Diplôme Universitaire Technologie, Applied Biology, Poitiers University, La Rochelle (1984)
- Ingenior in Biology, Clermont II University (1987)
- Master of Biology, Clermont II University (1987)
- PhD in Immunology, Claude Bernard University, Lyon, France (1992)
- Capacity to direct Research Programs within French Universities (HDR) (Lyon, 1999).
- INSERM Research Director (DR2) (2006)

PROFESSIONAL CAREER

- 1992-1998: Junior Scientist in Schering Plough, Lyon, France
- 1999- 2002: Principal Scientist and Group leader in Schering Plough, Lyon, France
- 2003- 2004: Head of Cellular and Molecular Biology department in Schering Plough
- Oct. 2004: Co-Director of Team « Cytokines and Cancers », INSERM U-590, CLB
- Jan. 2006: INSERM Research Director (DR2), INSERM U-590, Centre Léon Bérard, Lyon
- Jan. 2010: Director PI³, “Platform Innovation in Immunotherapy and Immuno-monitoring”, Centre Léon Bérard (CLB)
- Jan. 2011: Co-Director Team “Therapeutic targeting of tumor cell and its immune environment”, Cancer Research Center of Lyon (CRCL)
- Jan. 2017: Director of Team “Cancer Immune Surveillance and Therapeutic targeting”, CRCL
- Jan. 2019: Director LICL, “Laboratory of Immunotherapy of Cancer of Lyon”, CLB/CRCL

6 RECENT PUBLICATIONS

- Hubert M, ..., Caux C, Valladeau-Guilemond J. IFN-III is selectively produced by cDC1 and predicts good clinical outcome in breast cancer. *Science Immunol.* 5(46) 2020
- Shekarian T, Sivado E, Jallas AC, ..., Valsesia-Wittmann S, Caux C, Marabelle A. Repurposing rotavirus vaccines for intratumoral immunotherapy can overcome resistance to immune checkpoint blockade. *Sci Transl Med.* 11, 2019
- Ramos RN, Rodriguez C, Hubert M, ..., Barbuto JAM, Caux C, Ménétrier-Caux C, Bendriss-Vermare N. (2020) CD163+ tumor-associated macrophage accumulation in breast cancer patients reflects both local differentiation signals and systemic skewing of monocytes. *Clin Transl Immunology.* 2020 Feb 13;9(2):e1108.
- Gourdin N, Bossennec M, ..., Caux C *, Ménétrier-Caux C (*co-last). (2018) Autocrine Adenosine regulates tumor polyfunctional CD73+CD4+ effector T cells devoid of immune checkpoints *Cancer Research* 78(13); 3604-18.
- Small M*, Couillault C*, ..., Caux C, Dubois B*, Honnorat J*, Desestret V* (*co-last). (2018). Genetic alterations and tumor immune attack in Yo paraneoplastic cerebellar degeneration. *Acta Neuropathol.* 135, 569-579.
- Combes A, ..., Caux C, Bendriss-Vermare N, Pierre P & Gatti E (2017). BAD-LAMP controls TLR9 trafficking and signalling in human plasmacytoid dendritic cells. *Nature Comm.* 8(1):913
-
- Patents: 6 from his present work at INSERM (2004-2020).

HONORS AND AWARDS

- C Caux: Breast Cancer Research Foundation Grant 2005 and 2006
- Grand Prix de la Recherche Ruban Rose 2013 (association « Cancer du Sein Parlons 'En »)